Seek Returns

A vs. PFE: Agilent vs. Pfizer Stock Comparison

How do Agilent (A) and Pfizer (PFE) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Agilent (A) and Pfizer (PFE) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but A is classified in Life Sciences Tools & Services while PFE is classified in Pharmaceuticals.

Company profile comparison for Agilent (A) and Pfizer (PFE)
Profile ItemAPFE
NameAgileThought, Inc. Class A Common StockPfizer Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesPharmaceuticals
GICS Sub-IndustryLife Sciences Tools & ServicesPharmaceuticals
Market Capitalization49.28 billion USD167.52 billion USD
CurrencyUSDUSD
ExchangeNYSENYSE
Listing DateNovember 18, 1999June 1, 1972
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

A
PFE
GSPC
Loading price history…
Agilent (A) vs. Pfizer (PFE), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Agilent (A) and Pfizer (PFE). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Agilent (A) and Pfizer (PFE). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Agilent (A) and Pfizer (PFE)
MetricAPFE
Total Return (1Y)22.92%28.65%
Total Return (3Y, Annualized)19.33%6.41%
Total Return (5Y, Annualized)3.03%-3.98%

Risk Profile

Drawdown History

A
PFE
GSPC
Loading price history…
Agilent (A) vs. Pfizer (PFE), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Agilent (A) and Pfizer (PFE). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Agilent (A) and Pfizer (PFE)
MetricAPFE
Volatility (1Y, Annualized)33.10%21.72%
Beta (5Y)1.220.35
Max Drawdown (5Y)-38.09%-58.96%
Avg. Volume (3M)2.25M33.67M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
A and PFE are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Agilent (A) and Pfizer (PFE)
MetricAPFE
Sharpe Ratio (1Y)0.561.12
Sortino Ratio (1Y)0.961.73

Profitability

ROE (TTM)

Agilent (A) at 20.97% sits in the top ROE quartile, while Pfizer (PFE) at 4.47% is closer to the peer norm — stronger capital efficiency for A.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.97%

Max
109.18%
A
20.97%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.47%

Max
109.18%
Q3
6.23%
PFE
4.47%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Agilent (A) vs. Pfizer (PFE): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Agilent (A) at 19.53% keeps the most of each sales dollar — above its industry’s net margin range — and Pfizer (PFE) at 6.34% also retains a top-quartile share.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.53%

A
19.53%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.34%

Max
18.05%
PFE
6.34%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Agilent (A) vs. Pfizer (PFE): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Agilent (A) at 25.56% and Pfizer (PFE) at 33.38% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.56%

Max
83.12%
A
25.56%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.38%

Max
83.12%
PFE
33.38%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Agilent (A) vs. Pfizer (PFE): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Agilent (A) and Pfizer (PFE)
MetricAPFE
ROE (TTM)20.97%4.47%
ROA (TTM)8.63%5.59%
Net Margin (TTM)19.53%6.34%
Operating Margin (TTM)25.56%33.38%
Gross Margin (TTM)53.65%74.90%

Growth

Revenue Growth

Agilent (A) at 6.73% is around its peer norm for revenue growth, while Pfizer (PFE) at -1.65% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Loading chart…
Agilent (A) vs. Pfizer (PFE): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Agilent (A) at 3.16% and Pfizer (PFE) at -3.55% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Loading chart…
Agilent (A) vs. Pfizer (PFE): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Agilent (A) and Pfizer (PFE)
MetricAPFE
Revenue Growth (YoY)6.73%-1.65%
Revenue Growth (3Y CAGR)0.48%-14.80%
EPS Growth (YoY)3.16%-3.55%
EPS Growth (3Y CAGR)3.02%-37.12%

Financial Strength

Current Ratio (MRQ)

Both Agilent (A) at 2.05 and Pfizer (PFE) at 1.42 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.05

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
A
2.05
Min
0.10

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.42

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
PFE
1.42
Min
0.10
Loading chart…
Agilent (A) vs. Pfizer (PFE): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Agilent (A) at 0.56 carries an industry-typical debt-to-equity mix, while Pfizer (PFE) at 0.71 uses more debt funding than most peers.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.56

Max
1.42
Q3
0.65
A
0.56
Median
0.15
Q1
0.02
Min
0.00

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.71

Max
1.42
PFE
0.71
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Agilent (A) vs. Pfizer (PFE): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Agilent (A) and Pfizer (PFE)
MetricAPFE
Current Ratio (MRQ)2.051.42
Debt / Equity (MRQ)0.560.71
Net Debt / EBITDA1.151.97

Dividends

Dividend Yield (TTM)

Both Agilent (A) at 0.59% and Pfizer (PFE) at 7.30% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.59%

A
0.59%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.30%

PFE
7.30%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Agilent (A) vs. Pfizer (PFE): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Pfizer (PFE) reports payout ratio above 100% at 245.71%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Agilent (A) reports 19.98%, ranking against industry peers normally.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.98%

A
19.98%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

245.71%

PFE
245.71%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Agilent (A) vs. Pfizer (PFE): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Agilent (A) and Pfizer (PFE)
MetricAPFE
Dividend Yield (TTM)0.59%7.30%
Dividend Payout Ratio (TTM)19.98%245.71%

Valuation

P/E Ratio (TTM)

Both Agilent (A) at 34.47 and Pfizer (PFE) at 41.99 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

34.47

Max
85.34
Q3
43.46
A
34.47
Median
26.69
Q1
13.30
Min
0.07

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

41.99

Max
85.34
Q3
43.46
PFE
41.99
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Agilent (A) vs. Pfizer (PFE): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

Pfizer (PFE) at 2.63 sits in the cheaper P/S ratio quartile while Agilent (A) at 6.68 prices around its industry’s middle — PFE costs less per dollar of sales, though read it alongside growth and margins.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.68

Max
58.18
Q3
25.77
Median
7.30
A
6.68
Q1
3.01
Min
0.01

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.63

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
PFE
2.63
Min
0.01
Loading chart…
Agilent (A) vs. Pfizer (PFE): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Pfizer (PFE) at 1.88 is valued about in line with its industry on P/B ratio, while Agilent (A) at 6.69 carries an above-peer premium to book — A is pricier on assets.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.69

Max
13.53
A
6.69
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.88

Max
13.53
Q3
6.54
Median
3.25
PFE
1.88
Q1
1.69
Min
-5.59
Loading chart…
Agilent (A) vs. Pfizer (PFE): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Agilent (A) and Pfizer (PFE)
MetricAPFE
P/E Ratio (TTM)34.4741.99
P/S Ratio (TTM)6.682.63
P/B Ratio (MRQ)6.691.88
Free Cash Flow Yield (TTM)2.15%7.76%